Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease

Objectives: To evaluate the association of tumor-associated neutrophils (TANs) with malignant progression in intraductal papillary mucinous neoplasms (IPMNs) and to study the cyst fluid from these lesions for biomarkers of the inflammation-carcinogenesis association. Background: There is a strong link between TANs and malignant progression. Inflammatory mediators released by these cells may be a measurable surrogate marker of this progression. Methods: We evaluated 78 resected IPMNs (2004–2013). Lesions were divided into the low-risk (low- and intermediate-grade dysplasia: n = 48) and high-risk (high-grade dysplasia and invasive carcinoma: n = 30) groups. TANs were assessed and categorized (negative, low, and high). A multiplexed assay was performed to evaluate 87 different cyst fluid proteins, including cyst fluid inflammatory markers (CFIMs), as possible surrogate markers for parenchymal inflammation. Results: Significant positive correlation between grade of dysplasia and TANs was found. High levels of TANs were identified in 2%, 33%, and 89% of the lesions when stratified by grade of dysplasia into low/intermediate-grade dysplasia, high-grade dysplasia, and invasive carcinoma, respectively (P < 0.001). Higher grades of dysplasia were also found to have positive correlation with 29 of the measured proteins, of which 23 (79%) were CFIMs. Higher levels of TANs correlated with higher levels of 18 CFIMs, of which 16 (89%) were also found to be associated with higher grades of dysplasia. Conclusions: In this study, TANs were strongly associated with malignant progression in IPMNs. Measurement of CFIMs may be a surrogate marker for IPMN progression and allow for the identification of high-risk disease.

[1]  M. Gonen,et al.  Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. , 2011, Journal of the American College of Surgeons.

[2]  Jin‐Young Jang,et al.  Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Alyssa D Gregory,et al.  Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.

[4]  R. Hruban,et al.  Gastrointestinal Cancer : Targets and Therapy Precursors to invasive pancreatic cancer , 2012 .

[5]  M. Gonen,et al.  Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Annals of Surgical Oncology.

[6]  Olca Basturk,et al.  Tumor-infiltrating neutrophils in pancreatic neoplasia , 2011, Modern Pathology.

[7]  N. Jamieson,et al.  Exploiting inflammation for therapeutic gain in pancreatic cancer , 2013, British Journal of Cancer.

[8]  S. Itohara,et al.  Contribution of host MMP‐2 and MMP‐9 to promote tumor vascularization and invasion of malignant keratinocytes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  A. Warshaw,et al.  Cystic lesions in the pancreas: When to watch, when to resect , 2000, Current gastroenterology reports.

[10]  H. Pitt,et al.  Cystic Pancreatic Neoplasms: Observe or Operate , 2004, Annals of surgery.

[11]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[12]  C. Ko,et al.  Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma , 2010, Cancer.

[13]  C. Bassi,et al.  Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: Clinical Predictors of Malignancy and Long-term Survival Following Resection , 2004, Annals of surgery.

[14]  M. D'Angelica,et al.  Malignant Progression in IPMN: A Cohort Analysis of Patients Initially Selected for Resection or Observation , 2013, Annals of Surgical Oncology.

[15]  P. Allen The management of intraductal papillary mucinous neoplasms of the pancreas. , 2010, Surgical oncology clinics of North America.

[16]  A. Epstein,et al.  Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells , 2010, The Journal of Immunology.

[17]  L. Qin,et al.  Cyst Fluid Interleukin-1β (IL1β) Levels Predict the Risk of Carcinoma in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2011, Clinical Cancer Research.

[18]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[19]  M. Gonen,et al.  Predicting Dysplasia and Invasive Carcinoma in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Development of a Preoperative Nomogram , 2013, Annals of Surgical Oncology.

[20]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[21]  J. Cameron,et al.  Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas , 2010, Annals of surgery.

[22]  T. Whiteside,et al.  Tumor‐derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation , 2011, International journal of cancer.

[23]  A. Maitra,et al.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways , 2011, Proceedings of the National Academy of Sciences.

[24]  Jin-Young Jang,et al.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[25]  S. Lang,et al.  Peripheral Blood Neutrophil Granulocytes from Patients with Head and Neck Squamous Cell Carcinoma Functionally Differ from Their Counterparts in Healthy Donors , 2011, International journal of immunopathology and pharmacology.

[26]  A. Iafrate,et al.  Global Genomic Analysis of Intraductal Papillary Mucinous Neoplasms of the Pancreas Reveals Significant Molecular Differences Compared to Ductal Adenocarcinoma , 2009, Annals of surgery.

[27]  S. Chari,et al.  International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas , 2006, Pancreatology.

[28]  Heath B Acuff,et al.  Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. , 2006, Cancer research.

[29]  G. Rechavi,et al.  MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. , 2013, Surgery.

[30]  M. D'Angelica,et al.  Invasive Carcinoma Arising in Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Matched Control Study with Conventional Pancreatic Ductal Adenocarcinoma , 2011, Annals of surgery.

[31]  L. Qin,et al.  Pancreatic Cyst Fluid Protein Expression Profiling for Discriminating Between Serous Cystadenoma and Intraductal Papillary Mucinous Neoplasm , 2009, Annals of surgery.

[32]  Richard S. Kwon,et al.  Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification. , 2012, Journal of proteome research.